^
Association details:
| Biomarker: | PIK3CA mutation |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | taselisib (GDC-0032) (PIK3CA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Taselisib (GDC-0032), a Potent ß-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations
Excerpt:
The efficacy of GDC-0032 was assessed in vitro in 26 HNSCC cell lines with crystal violet proliferation assays, and changes in PI3K signaling were measured by Western blot analysis....GDC-0032 inhibited potently PI3K signaling and displayed greater antiproliferative activity in HNSCC cell lines with PIK3CA mutations...
DOI:
10.1158/1078-0432.CCR-15-2245
